Rex MD AI Visibility Market Strategy Report - ED Treatment Pills

Answer Capsule

Rex MD holds a small but real position in AI-generated recommendations for ED treatment pills, with 8.8% valid recommendation coverage in October 2026. The brand is visible in 14.5% of qualified AI responses but converts that presence into a valid recommendation less than two-thirds of the time, a gap that separates it from category leaders Hims (60.8%) and Ro (55.1%). Rex MD's clearest win is a 2.0% rank-one rate that exceeds several larger competitors, while its clearest weakness is a significant decline in raw mention presence from 21.2% in July to 14.5% in October. The biggest opportunity sits in the brand recommendation cluster, where Rex MD is being named less often even as it holds a modest first-position recommendation pocket.

Who This Report Is For

This report is for Rex MD's marketing, growth, and brand strategy teams, and for category analysts tracking how telehealth and online ED treatment brands are recommended across AI search surfaces.

Report Card

Executive Summary

Questions This Section Answers

• Where does Rex MD stand in valid recommendation coverage among ED treatment pill brands?
• What changed in Rex MD's AI visibility since the July 2026 baseline?
• Which platform drives Rex MD's strongest recommendation signal?

Rex MD enters October 2026 with 8.8% valid recommendation coverage, placing it eighth among ten tracked brands in the ED Treatment Pills benchmark. The brand is mentioned in 14.5% of qualified AI responses, but only 26 of those mentions convert into valid recommendations, a conversion gap that defines its current position. The benchmark shows Rex MD is visible but under-recommended relative to its presence rate.

The October reading represents a significant decline from the July 2026 baseline. Coverage fell 6.3 points from 15.1% to 8.8%, and raw mention presence fell 6.7 points from 21.2% to 14.5%. Both movements exceed normal month-to-month variation, indicating the brand is being named less often in AI responses, not only recommended less frequently.

The strongest signal for Rex MD is its rank-one rate. At 2.0%, the brand registers six first-position recommendations from a base of 26 valid recommendations. This rank-one rate exceeds BlueChew's 1.4% and Lemonaid Health's 1.4% in absolute terms. The brand has a narrow but meaningful pocket of first-position recommendation strength.

The weakest signal is the loss of mention presence. Rex MD's presence rate of 14.5% trails Lemonaid Health (36.5%), plushcare (30.7%), and BlueChew (21.6%), brands with comparable or smaller recommendation coverage. The brand is being displaced in the discovery layer before recommendation decisions are made.

Platform-level data shows Rex MD's strongest recommendation signal on Google AI Mode, where it holds a 6.2% valid recommendation coverage and a 2.5% rank-one rate. The brand has no presence on Perplexity in October 2026 and minimal presence on Copilot, where it registers a 3.9% rank-one rate but zero valid recommendation coverage.

The clearest gap is in the brand recommendation cluster, the only buyer-intent class with qualified observations in the October benchmark. All 296 qualified observations fell into this cluster, meaning Rex MD's entire measured AI visibility depends on discovery and consideration prompts where a specific treatment provider is sought. The brand is losing ground in exactly the prompt type that defines the category.

What Rex MD Is Winning

Questions This Section Answers

• How does Rex MD's rank-one rate compare with BlueChew, Lemonaid Health, and K Health?
• Where does Rex MD typically appear when it does receive a valid recommendation?
• Which AI platform produces the most Rex MD recommendations?

Rex MD's rank-one rate of 2.0% is its strongest recommendation metric. The brand registers six first-position recommendations in October 2026, up from zero in July 2026, a 2.0 point increase classified as significant. This places Rex MD ahead of BlueChew (1.4%), Lemonaid Health (1.4%), and K Health (0.0%) on first-position recommendation frequency.

The brand's average recommended rank of 2.58 is competitive. When Rex MD does receive a valid recommendation, it typically appears as the second or third option, ahead of plushcare (3.67), Lemonaid Health (3.24), and Blink Health (3.30). This placement quality suggests that when AI systems do recommend Rex MD, they position it favorably.

Rex MD shows no negative framing in the October data. The brand recorded zero negative mentions across 43 total mentions, with 30 positive and 13 neutral classifications. Its net sentiment score of 0.70 is positive, though lower than Lemonaid Health (0.91), GoodRx Care (0.84), and Hims (0.80).

The brand's strongest platform signal is Google AI Mode, where it holds 5 valid recommendations from 81 observations, a 6.2% coverage rate, and a 2.5% rank-one rate. This platform represents the largest single source of Rex MD's recommendation activity.

Where Rex MD Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Why is Rex MD's decline in raw mention presence a problem beyond recommendation coverage?
• Which competitors are capturing discovery-stage visibility that Rex MD has lost?
• Where does Rex MD have zero presence across AI platforms?

Rex MD's most significant gap is the decline in raw mention presence. The brand fell from 21.2% presence in July 2026 to 14.5% in October 2026, a 6.7 point drop classified as significant. This means AI systems are naming Rex MD less often in responses to ED treatment prompts, regardless of whether they recommend it. The brand is losing visibility at the discovery stage.

The recommendation conversion gap compounds this presence loss. Of the 43 observations where Rex MD is mentioned, only 26 result in valid recommendations. The brand converts 60.5% of its mentions into recommendations, compared to Hims at 65.7% (180 recommendations from 274 mentions) and Ro at 66.8% (163 recommendations from 244 mentions). Rex MD is being named but not shortlisted at a rate below category leaders.

Competitor displacement is evident in the presence metrics. Lemonaid Health, with 36.5% presence, is mentioned more than twice as often as Rex MD. plushcare, a new tracked entity in October 2026, holds 30.7% presence. BlueChew holds 21.6% presence. These brands are appearing in AI responses where Rex MD is absent, capturing discovery-stage visibility that Rex MD previously held.

The platform gap is most acute on Perplexity. Rex MD has zero presence on Perplexity in October 2026, meaning the brand does not appear in any of the 16 Perplexity observations captured in the benchmark. Competitors including Hims, Ro, GoodRx Care, plushcare, and Blink Health all register presence on this platform. Rex MD is absent from an entire AI surface family.

Copilot presents a different gap. Rex MD registers a 3.9% rank-one rate on Copilot but zero valid recommendation coverage. This suggests the brand occasionally appears as a first-position mention on Copilot but does not meet the threshold for valid recommendation credit, possibly because the mention lacks recommendation framing or appears in a comparison context.

The brand's top-three rate of 6.8% trails all competitors except Blink Health (1.4%), K Health (0.7%), and Optum (0.3%). Rex MD appears in the top three recommended options in only 20 of 296 qualified observations. Hims achieves this in 144 observations, Ro in 125, and GoodRx Care in 105. The gap to the recommendation shortlist is substantial.

Biggest Opportunity

Questions This Section Answers

• How can Rex MD turn its rank-one placements into broader shortlist presence?
• What prompt-level analysis is needed to recover the lost mention presence?

Rex MD's clearest path from reference to recommendation runs through the brand recommendation cluster, the only buyer-intent class currently measured in the benchmark. Within this cluster, the brand's opportunity is to convert its existing rank-one strength into broader shortlist presence.

The brand already demonstrates it can achieve first-position recommendations, registering six rank-one placements in October 2026. The opportunity is to expand the prompt themes where this occurs. If Rex MD can identify which specific question types produce its rank-one placements and build citation-supported evidence around those themes, it can extend its recommendation footprint without needing to compete directly with Hims and Ro across all prompts.

The diagnostic priority is to determine which prompt categories drove the loss in mention presence from July to October, and which brands now appear in Rex MD's place. The benchmark identifies the decline but does not reveal the prompt-level mechanics. A company-level analysis can map those patterns and identify the specific discovery prompts where Rex MD has lost visibility and where recovery is most achievable.

Competitive Landscape

Questions This Section Answers

• How does Rex MD's top-three rate compare with Hims, Ro, and GoodRx Care?
• Where does Rex MD rank in first-position recommendations relative to other ED treatment brands?

Hims and Ro hold recommendation-stage strength in the ED Treatment Pills category, with GoodRx Care emerging as a strong third. Rex MD sits in the lower tier of tracked brands, below Lemonaid Health and plushcare on recommendation coverage despite holding a competitive rank-one rate.

Average recommended rank covers rank-eligible recommendations only.

Rex MD's 6.76% top-three rate places it seventh among ten tracked brands, below BlueChew and plushcare despite holding a higher rank-one rate than both. The brand's 2.03% rank-one rate is the fourth-highest in the category, behind Hims, GoodRx Care, and Ro, indicating that when Rex MD does enter the recommendation set, it often enters at the top position. The gap is in frequency of shortlist inclusion, not in placement quality once included.

Prompt Evidence

Questions This Section Answers

• What did Rex MD's recommendations look like on Google AI Mode?
• Why did Rex MD register a rank-one mention on Copilot without valid recommendation credit?
• Which prompt surfaced Rex MD's absence on Perplexity?

Google AI Mode / Brand Recommendation Prompt: "What is the best generic Viagra?" Result: Rex MD received a valid recommendation with a rank-one placement, contributing to its 2.5% rank-one rate on this platform.

Copilot / Brand Recommendation Prompt: "ed meds online" Result: Rex MD appeared as a first-position mention but did not receive valid recommendation credit, reflecting the brand's zero valid recommendation coverage on Copilot despite a 3.9% rank-one rate.

Perplexity / Brand Recommendation Prompt: "telehealth companies" Result: Rex MD did not appear in the response, consistent with the brand's zero presence across all 16 Perplexity observations in October 2026.

Google AI Overviews / Brand Recommendation Prompt: "where to buy viagra" Result: Rex MD received a valid recommendation, contributing to its 13 valid recommendations and 10 top-three placements on this platform.

What CiteWorks Studio Would Do Next

Questions This Section Answers

• What are the first steps to audit Rex MD's lost mention presence?
• How would CiteWorks Studio extend Rex MD's rank-one strength to adjacent prompts?
• What owned content and citation work is needed to close Rex MD's platform gaps?

Phase 1: AI Market Discovery Audit Map the specific prompt themes where Rex MD lost mention presence between July and October 2026, and identify which competitors captured that visibility.

Phase 2: Recommendation Readiness Plan Prioritize the brand recommendation cluster prompts where Rex MD already achieves rank-one placements, and build a plan to extend that strength to adjacent question types.

Phase 3: Owned Answer Layer Buildout Develop owned content that directly addresses the discovery and consideration prompts where Rex MD is currently absent, with clear recommendation framing.

Phase 4: Citation / Authority Layer Development Strengthen the public evidence layer around Rex MD's differentiators, focusing on source types that AI systems already cite in this category, including health publishers and brand-owned domains.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track Rex MD's presence rate, valid recommendation coverage, and rank-one rate across all six AI surface families, with particular attention to Perplexity and Copilot where the brand currently has gaps.

Why This Matters

AI presence alone is not enough. Rex MD is mentioned in 14.5% of qualified AI responses, but only 8.8% of responses include a valid recommendation. The brand is visible but not consistently shortlisted, and the gap between presence and recommendation is where buyer decisions are lost.

The next move is targeted correction of the prompt, page, and citation layers. Rex MD's rank-one strength shows the brand can achieve first-position recommendations when it appears in the right context. The opportunity is to expand the contexts where that occurs, recover the mention presence lost since July, and close the platform gaps on Perplexity and Copilot.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Rex MD in October 2026: (30 × 1 + 13 × 0 + 0 × -1) / 43 = 0.6977

This score matters because unclassified mention counts are misleading. A brand with 43 mentions could appear strong, but if those mentions are neutral references or comparison anchors rather than recommendations, the visibility does not translate into buyer consideration. Rex MD's 0.70 sentiment score reflects a mix of positive recommendations and neutral references, with no negative framing.

Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because the difference between being recommended and being listed is the difference between being chosen and being considered.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Rex MD's AI visibility in the ED Treatment Pills category, using data from the LLM Authority Index October 2026 measurement.
2. The reporting window is October 2026, with comparison to the July 2026 baseline where available.
3. Six AI platform families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode. All six registered qualified observations in October 2026.
4. The October measurement began with 800 source prompt-surface observations, yielding 658 unique questions. After qualification, 296 observations remained as the public denominator for brand-level percentages.
5. The competitor universe includes ten tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, plushcare, BlueChew, Rex MD, Blink Health, K Health, and Optum.
6. Three public high-intent clusters were defined: Brand Recommendation (C01), Pricing & Value (C02), and Multi-Brand Comparison (C03). Only C01 contained qualified observations in October 2026.
7. Stage 0 extraction captured prompt-level observations including query, AI surface, answer, brand outcome, recommendation placement, sentiment, and citations where exposed.
8. A mention is defined as any appearance of Rex MD in an AI response, regardless of recommendation status.
9. A valid recommendation is defined as an appearance where Rex MD is explicitly recommended or shortlisted, meeting the benchmark's qualification criteria.
10. Average recommended rank covers rank-eligible recommendations only. Rex MD's average rank of 2.58 reflects its position when it receives valid rank credit.
11. The benchmark does not measure market share, sales, revenue attribution, organic search ranking, social media sentiment, or causality from metric movements.
12. Source presence in AI responses is evidence about the information environment and is not automatically proof that the source caused the recommendation.

See How AI Is Recommending Your Brand

The public benchmark shows where Rex MD stands in AI-generated recommendations for ED treatment pills. A company-level AI visibility audit can show why. The audit maps the specific prompts where Rex MD wins and loses, the competitors that capture recommendations when Rex MD is displaced, and the citation and evidence patterns that shape AI answers in this category.